The price-to-earnings ratio for Dexcom Inc (NASDAQ: DXCM) is above average at 102.66x, Company’s 36-month beta value is 1.21.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 8 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for DXCM is 377.37M, and currently, short sellers hold a 3.86% ratio of that floaft. The average trading volume of DXCM on April 16, 2024 was 3.06M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM)’s stock price has decreased by -1.16 compared to its previous closing price of 136.14. However, the company has seen a -3.84% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-15 that The Zacks Medical – Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.
DXCM’s Market Performance
Dexcom Inc (DXCM) has experienced a -3.84% fall in stock performance for the past week, with a 3.91% rise in the past month, and a 7.65% rise in the past quarter. The volatility ratio for the week is 2.61%, and the volatility levels for the past 30 days are at 2.90% for DXCM. The simple moving average for the last 20 days is -1.73% for DXCM stock, with a simple moving average of 17.16% for the last 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with RBC Capital Mkts repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to RBC Capital Mkts is $165 based on the research report published on March 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $131. The rating they have provided for DXCM stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Raymond James gave a rating of “Strong Buy” to DXCM, setting the target price at $138 in the report published on April 17th of the previous year.
DXCM Trading at 4.87% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.24% of loss for the given period.
Volatility was left at 2.90%, however, over the last 30 days, the volatility rate increased by 2.61%, as shares surge +3.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.76% upper at present.
During the last 5 trading sessions, DXCM fell by -3.84%, which changed the moving average for the period of 200-days by +6.44% in comparison to the 20-day moving average, which settled at $137.13. In addition, Dexcom Inc saw 8.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from SAYER KEVIN R, who sale 49,633 shares at the price of $138.30 back on Apr 08 ’24. After this action, SAYER KEVIN R now owns 283,893 shares of Dexcom Inc, valued at $6,864,136 using the latest closing price.
Brown Michael Jon, the EVP Chief Legal Officer of Dexcom Inc, sale 2,624 shares at $140.04 during a trade that took place back on Mar 28 ’24, which means that Brown Michael Jon is holding 68,682 shares at $367,472 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Dexcom Inc stands at 0.15. The total capital return value is set at 0.13. Equity return is now at value 25.78, with 9.29 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 1.25. The interest coverage ratio of the stock is 30.52.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 2.57. When we switch over and look at the enterprise to sales, we see a ratio of 14.88. The receivables turnover for the company is 3.67for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.84.
Conclusion
In a nutshell, Dexcom Inc (DXCM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
